A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Two Period Crossover, Single Dose-Finding Study to Assess the Efficacy and Safety of Controlled Release XP19986 in Patients With Gastroesophageal Reflux Disease.
Phase of Trial: Phase II
Latest Information Update: 16 Sep 2016
At a glance
- Drugs Arbaclofen placarbil (Primary)
- Indications Gastro-oesophageal reflux
- Focus Therapeutic Use
- Sponsors XenoPort
- 29 Dec 2009 Primary endpoint 'Gastrointestinal symptoms' has been met.
- 29 Dec 2009 Results published in The American Journal of Gastroenterology.
- 09 Dec 2009 New source identified and integrated (ClinicalTrials.gov record no. NCT00838396).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History